Harald Reinhart - 01 Jan 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Issuer symbol
ZLAB
Transactions as of
01 Jan 2024
Net transactions value
-$125,464
Form type
4
Filing time
03 Jan 2024, 19:25:23 UTC
Previous filing
26 Jun 2023
Next filing
03 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +17,548 +53% 50,863 01 Jan 2024 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale $125,464 -4,803 -9.4% $26.12 46,060 03 Jan 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Performance-Based Share Units Award $0 +17,548 $0.000000 17,548 01 Jan 2024 American Depositary Shares 17,548 Direct F1, F3, F5
transaction ZLAB Performance-Based Share Units Options Exercise $0 -17,548 -100% $0.000000* 0 01 Jan 2024 American Depositary Shares 17,548 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired on vesting of performance-based share units (PSUs). Each ADS represents ten Ordinary Shares of the issuer.
F3 Each PSU represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
F4 These ADSs were sold automatically to cover taxes upon vesting of PSUs.
F5 The reporting person was granted PSUs on December 1, 2021 that vest based on the satisfaction of specified performance criteria between December 1, 2021 and December 31, 2025. On January 1, 2024, the performance-based vesting conditions were confirmed for PSUs representing 17,548 ADSs.

Remarks:

President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases